AhR modulator-1AhR modulator-1
MedChemExpress (MCE)
HY-135671
118174-38-2
Please store the product under the recommended conditions in the Certificate of Analysis.
Room temperature in continental US
may vary elsewhere.
AhR modulator-1 (compound 6-MCDF) is a selective and orally active aryl hydrocarbon receptor (AhR) modulator. AhR modulator-1 inhibits metastasis, in part, by inhibiting prostatic VEGF production prior to tumor formation. AhR modulator-1 also possess anti-estrogenic properties in rat uterus.
AhR modulator-1 (6-MCDF
0.1-10 μM
48-96 hours
ASPC-1 cells) treatment exhibits dose-dependent growth inhibitory effects with growth inhibitory effects of 26, 43 and 99% at concentrations of 0.1, 1 and 10 μM, respectively[2].
AhR modulator-1 (6-MCDF
0-40 mg/kg
oral administration
daily
for 12 weeks
C57BL/6-Tg(TRAMP)8247Ng/J mice) treatment reduces the frequency of pelvic lymph node metastasis in mice fed the 40 mg/kg diet. And serum VEGF concentrations are also reduced. Prostate tumor incidence and size are not significantly reduced[1].
Aryl hydrocarbon receptor (AhR) [1][2] Prostatic VEGF[1] Estrogenic[1] In Vitro AhR modulator-1 (6-MCDF
0.1-10 μM
48-96 hours
ASPC-1 cells) treatment exhibits dose-dependent growth inhibitory effects with growth inhibitory effects of 26, 43 and 99% at concentrations of 0.1, 1 and 10 μM, respectively[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> AhR modulator-1 Related Antibodies Cell Proliferation Assay[2] Cell Line: ASPC-1 cells
| | | |
| | | | | |
[1]. Fritz WA, et al. The selective aryl hydrocarbon receptor modulator 6-methyl-1,3,8-trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice. Biochem Pharmacol. 2009 Apr 1
77(7):1151-60. [Content Brief]
[2]. Koliopanos A, et al. Increased arylhydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer. Oncogene. 2002 Sep 5
21(39):6059-70. [Content Brief]